Teva says court lifts stay of approval against generic Pravachol, Apotex files appeal

By Elaine Rigoli

Tampa, Fla., April 20 - Teva Pharmaceutical Industries, Ltd. said the U.S. District Court for the District of Columbia has granted the company's motion to reconsider the stay of approval of its Abbreviated New Drug Application (ANDA) to market its generic version of Pravachol (pravastatin sodium) tablets, 10 mg, 20 mg and 40 mg, a cholesterol-reducing drug manufactured originally by Bristol-Myers Squibb Co.

The court's denial of Apotex's motion for a temporary restraining order and preliminary injunction remains in place.

Apotex has appealed those denials to the Court of Appeals for the District of Columbia and has asked that the appellate court enter a stay of approval of Teva's ANDA pending a decision on the appeal, according to a news release.

Apotex is a pharmaceutical company based in Weston, Fla.

Teva is a generic pharmaceutical company based in Jerusalem.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.